Although reduced-intensity conditioning (RIC) and nonmyeloablative (NMA)-conditioning regimens have been used for over a decade, their relative efficacy vs myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation in patients with AML and myelodysplasia (MDS) is unknown. We compared disease status, donor, graft and recipient characteristics with outcomes of 3731 MA with 1448 RIC/NMA procedures performed at 217 centers between 1997 and 2004. The 5-year univariate probabilities and multivariate relative risk outcomes of relapse, TRM, disease-free survival (DFS) and OS are reported. Adjusted OS at 5 years was 34, 33 and 26% for MA, RIC and NMA transplants, respectively. NMA conditioning resulted in inferior DFS and OS, but there was no difference in DFS and OS between RIC and MA regimens. Late TRM negates early decreases in toxicity with RIC and NMA regimens. Our data suggest that higher regimen intensity may contribute to optimal survival in patients with AML/ MDS, suggesting roles for both regimen intensity and graft vs leukemia in these diseases. Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning.
Introduction
Allogeneic hematopoietic cell transplantation offers a chance of long-term disease-free survival (DFS) to patients with high-risk AML or myelodysplasia (MDS), with 5-year survival ranging from 30-50%. [1] [2] [3] Many patients with AML are not considered candidates for standard myeloablative (MA) procedures because of advanced age, previous therapies or comorbidities. Non-myeloablative (NMA) and reduced-intensity conditioning (RIC) regimens were developed over a decade ago to reduce the TRM of MA hematopoietic cell transplantation, and to allow patients otherwise ineligible for allogeneic transplant to benefit from the graft vs leukemia effect. [4] [5] [6] [7] AML and MDS are now considered standard indications for NMA or RIC transplants, and a number of studies have demonstrated durable long-term remissions using these approaches. [8] [9] [10] [11] [12] [13] [14] Several groups have retrospectively compared RIC with MA conditioning for allotransplantation in AML and MDS, [15] [16] [17] [18] and suggest that RIC allografts can yield satisfactory survival for patients who are ineligible for MA allografts. To better address the important question of whether the intensity of the preparative regimens used for AML/MDS correlates with survival and other key outcomes, we performed a comparative analysis of outcomes of transplants reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) after MA, RIC and NMA preparatory regimens. In addition, we report the association of specific donor, graft and recipient characteristics with key outcomes when each of these three approaches is utilized.
Patients and methods

Data sources
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry, Autologous Blood and Marrow Transplant Registry and the National Marrow Donor Program (NMDP) established in 2004 that comprises a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on allogeneic and autologous hematopoietic SCT to a Statistical Center at the Medical College of Wisconsin in Milwaukee and the NMDP Coordinating Center in Minneapolis. Participating centers are required to report all transplants consecutively. Patients are followed longitudinally, with yearly follow-up. Computerized checks for discrepancies, physicians' review of submitted data and onsite audits of participating centers ensure data quality and compliance. Observational studies conducted by the CIBMTR are performed in compliance with the Privacy Rule (HIPAA) as a Public Health Authority, and in compliance with all applicable federal regulations pertaining to the protection of human research participants as determined by continuous review of the Institutional Review Boards of the NMDP and the Medical College of Wisconsin since 1985.
The CIBMTR collects data at two levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF) data. TED includes disease type, age, sex, pretransplant disease stage and chemotherapy responsiveness, date of diagnosis, graft type (BM-and/or blood-derived stem cells), high-dose-conditioning regimen, posttransplant disease progression and survival, development of a new malignancy and cause of death. All CIBMTR teams contribute to TED. More detailed disease, and pre-and posttransplant clinical information are collected on a subset of registered patients selected for CRF data by a weighted randomization scheme. TED-and CRF-level data are collected before transplant, 100 days and 6 months after transplant, and annually thereafter or until death.
Patients, donors and graft source
The study included all patients between the ages of 18 and 70 years, who received PBSC or BM grafts from a related or volunteer unrelated donor (URD) for MDS or non-M3 AML reported to the CIBMTR between 1997 and 2004, on whom adequate data were available for analysis. Excluded were recipients of cord blood transplants, transplants performed with a conditioning regimen that was used in fewer than 30 patients and transplants in which patients received T-cell-depleted grafts.
Conditioning regimens
The regimens were defined as MA, RIC and NMA using previously defined guidelines as follows: 19, 20 MA regimens included (1) TBI dose 4500 cGy, single dose or TBI dose X800 cGy fractionated, with or without CY, (2) standard dose of BU and CY, (3) melphalan X150 mg/m 2 ± other agents and (4) BU total dose 49 mg/kg±other agents. RIC regimens included (1) TBI dose 4200 cGy and o500 cGY single dose or TBI dose o800 cGY fractionated ± other agents, (2) melphalan dose p150 mg/m 2 ±other agents and (3) BU dose p9 mg/kg ± other agents. NMA regimens included were (1) TBI alone 200 cGY, (2) fludarabine þ TBI 200 cGY or (3) fludarabine þ CY.
End points
Primary end points were hematopoietic recovery, GVHD, TRM, clinical disease relapse (hematological or extramedullary), DFS, and OS. TRM was defined as death during continuous CR after transplant. Relapse was defined as clinical or hematological recurrence. For analyses of DFS, failures were clinical or hematological relapses or deaths from any cause; patients alive and in CR were censored at the time of last follow-up. For analyses of OS, failure was death from any cause; surviving patients were censored at the date of last contact. The date of the transplant was the starting time point for calculating all outcomes.
Statistical analysis
Patient-, disease-and transplant-related variables for patients receiving MA-, RIC-and NMA-conditioning regimens were compared using the w 2 -statistic for categorical variables and the Kruskal-Wallis test for continuous variables. Univariate probabilities of DFS and OS were calculated using the Kaplan-Meier estimator; the log-rank test was used for univariate comparisons. Probabilities of hematopoietic recovery, acute and chronic GVHD, TRM and relapse were calculated using cumulative incidence curves to accommodate competing risks. 21 Assessments of potential risk factors for outcomes of interest were evaluated in multivariate analyses using Cox proportional hazards regression. 22 The variables considered in the multivariate analysis were age at transplant, gender, Karnofsky performance score (o90 vs X90% vs unknown), disease (AML vs MDS)), FAB subtype at diagnosis (M0-M2 vs M4-M7 vs other/unclassified (for AML), refractory anemia or acquired idiopathic sideroblastic anemia vs other MDS (for MDS), therapy-related leukemia (no vs yes vs unknown), cytogenetics (good vs intermediate vs poor prognosis vs unknown), blast percentage at transplant (o5 vs 5-10 vs 410% vs unknown), duration of first CR for AML patients transplanted in second CR (o6 vs 6-12 months vs unknown), disease status at transplant (primary induction failure vs first CR vs Xsecond CR vs relapse (for AML), treated vs untreated (for MDS), time from remission to transplant for AML patients transplanted in first CR (p3 vs 43 months vs unknown), type of donor (HLA-identical sibling vs unrelated well-matched vs unrelated partially matched vs unrelated mismatched vs unrelated matching unknown), donor age, donor-recipient sex match (female-male vs others), donor-recipient CMV status (donorÀ/recipientÀ vs donor þ /recipientÀ vs recipient þ vs unknown), graft type (BM vs PBSCs), year of transplant, previous autologous transplant (no vs yes), anti-thymocyte globulin (ATG) (no vs yes) and GVHD prophylaxis (tacrolimus þ MTX ± other vs tacrolimus ± other vs CYA þ MTX ± other vs CYA ± other). A backward stepwise model selection approach was used to identify all significant risk factors. Each step of model building contained the main effect for conditioning regimen. Factors that were significant at a 5% level were kept in the final model. The potential interactions between main effect and all significant risk factors were tested. A significant interaction was found between graft type and reduced-intensity-conditioning regimen. A model with this interaction was considered for this group. The proportionality assumption was tested by adding a time-dependent covariate for each factor. When tests indicated differential effects over time (non-proportional hazards), models were constructed breaking the after transplant course into two time periods using the maximized partial likelihood method to find the most appropriate break point. The proportionality assumptions were further tested. After the above modeling of time varying effects, the final multivariate model was built. Adjusted probabilities of DFS and OS were generated from the final Cox models, stratified on treatment of conditioning regimen and weighted averages of covariate values using the pooled sample proportion as the weight function. These adjusted probabilities were used to estimate likelihood of outcomes in populations with similar prognostic factors. Patients who were in the NMA group were more likely to be transplanted more than 3 months after attaining remission (Po0.002).
Results
Patient and transplant characteristics
Hematopoietic recovery
Hematopoietic recovery at 100 days was similar for the conditioning regimen categories. The likelihood of achieving an ANC of 500 on day 100 was 93 vs 92 vs 95 vs 94% for MA vs RIC conditioning with BM, RIC with PBSC, and NMA conditioning.
GVHD
The incidence of grade II-IV acute GVHD (aGVHD) by day 100 was lower in the RIC BM group (relative risk 0.66, (0.51-0.85), P ¼ 0.001), with 41% of patients developing aGVHD compared with 45-47% in the MA, RIC PBSC and NMA groups (Figure 1a ). Chronic GVHD was more likely in RIC PBSC-and NMA-conditioned recipients (almost all of whom received PBSC) when compared with MA-conditioned recipients and least likely with RIC-conditioned recipients who received BM (Figure 1b ). Table 2 demonstrates the results of the multivariate analysis of TRM. There was no statistically significant difference in TRM between the four groups. Early on (at 3 and 6 months), there was slightly higher TRM in the MA and RIC BM groups when compared with RIC PBSC and NMA (3-month TRM 18, 16, 12 and 13% for MA vs RIC BM vs RIC PBSC vs NMA, respectively). However, by 3 years, TRM was equivalent among the four groups (Figure 2a ) and this continued at 5 years.
Treatment-related mortality
Relapse and survival
Relapse was more likely in the RIC BM and NMA groups than in the MA group (Po0.001; Table 2 ). At 5 years, cumulative incidence of relapse was 32, 42, 39 and 43% for the MA-vs RIC BM-vs RIC PBSC-vs NMA-conditioned groups, respectively (Figure 2b ). Treatment failure (relapse or death in remission) was greatest and DFS was lowest among the NMA group (Po0.001, Table 2 ). The adjusted DFS probability at 5 years was 33, 29, 30 and 24% for the MA-, RIC PBSC-, RIC BM-and NMA-conditioned groups, respectively (Po0.001 for NMA compared with MA conditioning; Figure 3a ).
Overall mortality was highest for patients who underwent NMA transplants (relative risk 1.2, P ¼ 0.006). Adjusted OS at 5 years was 34, 33, 33 and 26% for MA, RIC PBSC, RIC BM and NMA transplants, respectively (Figure 3b ).
Primary disease, infection and GVHD accounted for the majority of deaths. Patients in the NMA group were more likely to die of primary disease (43 vs 37% for MA/RIC PBSC and 34% for RIC BM). Death from infection was more likely in RIC transplants than MA and NMA transplants (22 vs 16% for RIC vs MA/NMA, respectively, P ¼ 0.009).
Potential candidates for ablative and non-ablative conditioning
We performed a subset analysis of patients who had better risk disease, a high performance score and were in an age range where many clinicians would consider using any of the three approaches. This subgroup consisted of patients between the ages of 40-60 years with AML in CR1 or with early MDS (o5% blasts) and with a Karnofsky score of X90%. Similar to the entire group, DFS at 5 years was 43, 37, 33 and 26% for MA vs RIC BM vs RIC PBSC vs NMA, respectively (Table 3) . Only the NMA group had an inferior outcome compared with the MA group (P ¼ 0.006).
Discussion
This study describes the largest group of patients with AML and MDS who have received allogeneic transplant with MA, RIC and NMA conditioning reported to date. It includes transplantation from both related and unrelated donors from multiple centers. The key finding of our study is that in spite of varying regimen intensities for older and sicker patients previously ineligible for allogeneic transplantation, differences in survival outcomes are very small. RIC and NMA yielded similar OS and DFS. Only NMA conditioning (defined here as TBI 200 cGy ± fludarabine or fludarabine þ CY) resulted in significantly worse long-term DFS and OS compared with the more intense preparative approaches.
Although RIC and NMA regimens are thought to decrease the risk of early morbidity and aGVHD because of decreased tissue damage, conditioning intensity did not significantly impact the incidence of aGVHD. Although donor type impacted on the probability of both acute and chronic GHVD, in multivariate analysis, only age and type of GVHD prophylaxis impacted the incidence of chronic GVHD.
MA regimens were associated with less relapse than the RIC BM and NMA groups. Increased blast percentage at transplant, late disease status and poor-risk cytogenetics were associated with relapse, but surprisingly, so was a lower Karnofsky score. Age, performance status and disease status at transplant were significant covariates for TRM and were significantly different between the various transplant types. Although early TRM was less with RIC/ NMA approaches, the data indicate that late TRM negates any early advantage offered by RIC regimens, resulting in similar 5-year DFS and OS in recipients of MA conditioning. Late TRM after RIC/NMA approaches was due to similar causes compared with MA approaches, primarily infections and GVHD. In a retrospective review of RIC vs MA sibling-matched transplants in 722 patients with AML over the age of 50 years from the European Group for Blood and Marrow Transplantation (EBMT), 23 aGVHD (grades II-IV) and TRM (at 2 years) were decreased, and relapse rate was increased following RIC procedures on univariate analysis. The study was not, however, able to demonstrate any difference in leukemia-free survival and OS at 2 years. A recent EBMT study comparing MA conditioning vs RIC in patients with AML receiving unrelated donor transplants showed that in patients below 50 years of age, relapse was increased following RIC, but TRM and leukemia-free survival were the same in each group. [23] [24] [25] In patients above 50 years of age, TRM was increased in the MA group, but relapse and leukemia-free survival were the same.
Martino et al. 26 reported results on 836 patients with MDS or secondary AML who received RIC vs MA sibling transplants. They noted an increase in relapse rate with RIC but no difference in progression free or OS. For patients under the age of 50 years, however, the 3-year incidence of relapse and TRM was lower for those who received MA conditioning compared with RIC (57 vs 69%). It is possible that patients under 50 years of age who received RIC had other comorbidities or risk factors that would have contributed to an inferior outcome. In their study, for patients who were transplanted not in CR, there was a lower incidence of relapse and TRM for those patients who had MA rather than RIC (68 vs 90%). In our study, multivariate analysis showed that blast percentage and disease status at transplant were also found to be significant covariates for both DFS and OS. Also, DFS and OS were also not different for the treatment related AML (t-AML)/MDS subgroup. In our subanalysis of patients between the ages of 40 and 60 years with AML in CR1 or with MDS potentially eligible for any conditioning approach, we observed similar DFS when comparing MA with RIC transplant approaches, but inferior survival using NMA regimens.
As with all retrospective registry studies, heterogeneity of patients may affect our analysis. Additionally, the reason for choice of preparative regimens is not known. The NMA group was older and had a lower Karnofsky score at transplant. Many patients who received RIC or NMA transplants would not have been candidates for MA transplants. Detailed comorbidity descriptions or data allowing formal comorbidity scoring were not available. Although the known cofactors affecting outcome are accounted for as much as possible in our analyses and adjusted for in the DFS and OS assessments, the analysis presented here cannot be used to determine the optimal treatment for any given patient. These data do suggest, however, that NMA/RIC conditioning yields durable long-term survival for a sizeable fraction of patients with AML/MDS, and therefore is a treatment option that can be considered. NMA conditioning is associated with more relapse, resulting in inferior DFS and OS compared with the other levels of regimen intensity. This finding supports a hypothesis that some level of conditioning intensity above typical NMA approaches may improve survival in AML/ MDS. Further support for this hypothesis is provided by the higher rate of relapse and decrease in DFS after NMA regimens noted in the subgroup analysis that we performed on patients with better risk disease between ages 40 and 60 years, who had the potential of receiving MA, RIC or NMA approaches. Having said that, patients receiving NMA conditioning may differ in unknown ways from patients receiving the more intensive regimens. Prospective studies randomizing these regimens in defined populations are warranted to determine optimal approaches for patients based upon patient, disease and donor characteristics.
